Rosuvastatin Calcium

ROSUVASTATIN CALCIUM — rosuvastatin calcium tablet, film coated
MSN LABORATORIES PRIVATE LIMITED

1 INDICATIONS AND USAGE

Rosuvastatin tablets are indicated:

  • To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor.
  • As an adjunct to diet to:
    o Reduce LDL-C in adults with primary hyperlipidemia.
    o Reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults.
    o Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
  • As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).
  • As an adjunct to diet for the treatment of adults with:
    o Primary dysbetalipoproteinemia.
    o Hypertriglyceridemia.

2 DOSAGE AND ADMINISTRATION

2.1 General Dosage and Administration Information

  • Administer rosuvastatin calcium orally as a single dose at any time of day, with or without food. The tablet should be swallowed whole.
  • Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin calcium, and adjust the dosage if necessary.
  • If a dose is missed, advise patients not take an extra dose. Resume treatment with the next dose.

2.2 Recommended Dosage in Adult Patients

  • The dosage range for rosuvastatin calcium is 5 to 40 mg orally once daily.
  • The recommended dose of rosuvastatin calcium depends on a patient’s indication for usage, LDL-C, and individual risk for cardiovascular events.

2.3 Recommended Dosage in Pediatric Patients

Dosage in Pediatric Patients 8 Years of Age and Older with HeFH

The recommended dosage range is 5 mg to 10 mg orally once daily in patients aged 8 years to less than 10 years and 5 mg to 20 mg orally once daily in patients aged 10 years and older.

Dosage in Pediatric Patients 7 Years of Age and Older with HoFH

2.4 Dosing in Asian Patients

Initiate rosuvastatin calcium at 5 mg once daily due to increased rosuvastatin plasma concentrations. Consider the risks and benefits of rosuvastatin calcium when treating Asian patients not adequately controlled at doses up to 20 mg once daily [see Warnings and Precautions (5.1), Use in Specific Populations (8.8), and Clinical Pharmacology (12.3)].

2.5 Recommended Dosage in Patients with Renal Impairment

In patients with severe renal impairment (CLcr less than 30 mL/min/1.73 m2) not on hemodialysis, the recommended starting dosage is 5 mg once daily and should not exceed 10 mg once daily [see Warnings and Precautions (5.1) and Use in Specific Populations (8.6)]. There are no dosage adjustment recommendations for patients with mild and moderate renal impairment.

2.6 Dosage and Administration Modifications Due to Drug Interactions

Rosuvastatin Calcium Dosage Modifications Due to Drug Interactions
Table 1 displays dosage modifications for rosuvastatin calcium due to drug interactions [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].
Table 1: Rosuvastatin calcium Dosage Modifications Due to Drug Interactions

Concomitantly Used Drug Rosuvastatin calcium Dosage Modifications
Cyclosporine Do not exceed 5 mg once daily.
Teriflunomide Do not exceed 10 mg once daily.
Enasidenib Do not exceed 10 mg once daily.
Capmatinib Do not exceed 10 mg once daily.
Fostamatinib Do not exceed 20 mg once daily.
Febuxostat Do not exceed 20 mg once daily.
Gemfibrozil Avoid concomitant use. If used concomitantly, initiate at 5 mg once daily and do not exceed 10 mg once daily.
Tafamidis Avoid concomitant use. If used concomitantly, initiate at 5 mg once daily and do not exceed 20 mg once daily.
Antiviral Medications
o Sofbuvir/velpatasvir/voxilaprevir o Ledipasvir/sofosbuvir Concomitant use not recommended.
o Simeprevir o Dasabuvir/ombitasvir/paritaprevir/ritonavir o Elbasvir/Grazoprevir o Sofosbuvir/Velpatasvir o Glecaprevir/Pibrentasvir o Atazanavir/Ritonavir o Lopinavir/Ritonavir Initiate at 5 mg once daily. Do not exceed 10 mg once daily.
Darolutamide Do not exceed 5 mg once daily.
Regorafenib Do not exceed 10 mg once daily.

Rosuvastatin Calcium Administration Modifications Due to Drug Interactions
When taking rosuvastatin calcium with an aluminum and magnesium hydroxide combination antacid, administer rosuvastatin calcium at least 2 hours before the antacid [see Drug Interactions (7.2)].

3 DOSAGE FORMS AND STRENGTHS

Rosuvastatin tablets, USP:

  • 5 mg: White, round shaped, biconvex film coated tablets debossed with”R5″ on one side and plain on other side.
  • 10 mg: Pink, round shaped, biconvex, film coated tablets debossed with “R10” on one side and plain on other side.
  • 20 mg: Pink, round shaped, biconvex, film coated tablets debossed with “R20” on one side and plain on other side.
  • 40 mg: Pink, oval shaped, biconvex, film coated tablets debossed with “R” on one side and “40” on other side.

4 CONTRAINDICATIONS

Rosuvastatin calcium is contraindicated in the following conditions:

  • Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3)].
  • Hypersensitivity to rosuvastatin or any excipients in rosuvastatin calcium. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin calcium [see Adverse Reactions (6.1)].

5 Rosuvastatin Calcium Warnings and Precautions

5.1 Myopathy and Rhabdomyolysis

Rosuvastatin calcium may cause myopathy [muscle pain, tenderness, or weakness associated with elevated creatine kinase (CK)] and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis with statins, including rosuvastatin calcium.
Risk Factors for Myopathy
Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs (including other lipid-lowering therapies), and higher rosuvastatin calcium dosage. Asian patients on rosuvastatin calcium may be at higher risk for myopathy [see Drug Interactions (7.1)and Use in Specific Populations (8.8)]. The myopathy risk is greater in patients taking rosuvastatin calcium 40 mg daily compared with lower rosuvastatin calcium dosages.
Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis
The concomitant use of rosuvastatin calcium with cyclosporine or gemfibrozil is not recommended. Rosuvastatin calcium dosage modifications are recommended for patients taking certain antiviral medications, darolutamide, and regorafenib [see Dosage and Administration (2.6)]. Niacin, fibrates, and colchicine may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions (7.1)].
Discontinue rosuvastatin calcium if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Muscle symptoms and CK elevations may resolve if rosuvastatin calcium is discontinued. Temporarily discontinue rosuvastatin calcium in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy). Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the rosuvastatin calcium dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2024. All Rights Reserved.